Agenus Inc (AGEN) stock
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.29−0.44 (-6.54%)
Close on Nov 16, 2026Market cap $283.18MP/E –Yield –
Agenus r&d expenses
Research and development expenses are spending on new products and technology.
Agenus's R&D Expenses for the twelve months ending Jun 30, 2026 was $57.69M, down 53.1% year over year. For fiscal 2025 it was $79.34M, down 49.0% from the year before. Over ten years it grew 1.2% a year on average. The highest annual figure on record is $234.57M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.34M | -49.0% |
| FY2024 | Dec 31, 2024 | $155.53M | -33.7% |
| FY2023 | Dec 31, 2023 | $234.57M | +25.6% |
| FY2022 | Dec 31, 2022 | $186.69M | +4.5% |
| FY2021 | Dec 31, 2021 | $178.61M | +25.2% |
| FY2020 | Dec 31, 2020 | $142.62M | -15.3% |
| FY2019 | Dec 31, 2019 | $168.34M | +35.1% |
| FY2018 | Dec 31, 2018 | $124.60M | +7.3% |
| FY2017 | Dec 31, 2017 | $116.13M | +22.3% |
| FY2016 | Dec 31, 2016 | $94.97M | +34.8% |
| FY2015 | Dec 31, 2015 | $70.44M | +215.2% |
| FY2014 | Dec 31, 2014 | $22.35M | +71.8% |
| FY2013 | Dec 31, 2013 | $13.01M | +23.1% |
| FY2012 | Dec 31, 2012 | $10.56M | -4.2% |
| FY2011 | Dec 31, 2011 | $11.02M | -14.4% |
| FY2010 | Dec 31, 2010 | $12.88M | -23.8% |
| FY2009 | Dec 31, 2009 | $16.90M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.76M | -44.7% |
| Q1 FY2026 | Mar 31, 2026 | $11.82M | -45.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.51M | -77.8% |
| Q3 FY2025 | Sep 30, 2025 | $23.60M | -42.5% |
| Q2 FY2025 | Jun 30, 2025 | $26.71M | -27.4% |
| Q1 FY2025 | Mar 31, 2025 | $21.52M | -51.0% |
| Q4 FY2024 | Dec 31, 2024 | $33.78M | -49.4% |
| Q3 FY2024 | Sep 30, 2024 | $41.06M | -20.2% |
| Q2 FY2024 | Jun 30, 2024 | $36.77M | -38.0% |
| Q1 FY2024 | Mar 31, 2024 | $43.93M | -23.1% |
| Q4 FY2023 | Dec 31, 2023 | $66.72M | +25.2% |
| Q3 FY2023 | Sep 30, 2023 | $51.44M | +11.8% |
| Q2 FY2023 | Jun 30, 2023 | $59.29M | +31.9% |
| Q1 FY2023 | Mar 31, 2023 | $57.12M | +34.6% |
| Q4 FY2022 | Dec 31, 2022 | $53.28M | -0.4% |
| Q3 FY2022 | Sep 30, 2022 | $46.01M | +7.2% |
| Q2 FY2022 | Jun 30, 2022 | $44.96M | -1.2% |
| Q1 FY2022 | Mar 31, 2022 | $42.44M | +15.7% |
| Q4 FY2021 | Dec 31, 2021 | $53.49M | +50.4% |
| Q3 FY2021 | Sep 30, 2021 | $42.94M | +33.6% |
| Q2 FY2021 | Jun 30, 2021 | $45.51M | +18.0% |
| Q1 FY2021 | Mar 31, 2021 | $36.68M | +0.9% |
| Q4 FY2020 | Dec 31, 2020 | $35.57M | -3.4% |
| Q3 FY2020 | Sep 30, 2020 | $32.13M | -30.3% |
| Q2 FY2020 | Jun 30, 2020 | $38.55M | -14.8% |
| Q1 FY2020 | Mar 31, 2020 | $36.36M | -9.4% |
| Q4 FY2019 | Dec 31, 2019 | $36.83M | +2.2% |
| Q3 FY2019 | Sep 30, 2019 | $46.13M | +54.5% |
| Q2 FY2019 | Jun 30, 2019 | $45.24M | +54.6% |
| Q1 FY2019 | Mar 31, 2019 | $40.13M | +36.3% |
| Q4 FY2018 | Dec 31, 2018 | $36.03M | +13.0% |
| Q3 FY2018 | Sep 30, 2018 | $29.85M | +15.8% |
| Q2 FY2018 | Jun 30, 2018 | $29.27M | +13.4% |
| Q1 FY2018 | Mar 31, 2018 | $29.44M | -9.8% |
| Q4 FY2017 | Dec 31, 2017 | $31.87M | +22.7% |
| Q3 FY2017 | Sep 30, 2017 | $25.79M | +19.5% |
| Q2 FY2017 | Jun 30, 2017 | $25.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $32.64M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.98M | – |
| Q3 FY2016 | Sep 30, 2016 | $21.59M | – |
See a number that looks wrong?